The press conference also featured a presentation by Christopher Inglefield, M.D., Medical Director and Owner of the London Bridge Plastic Surgery & Aesthetic Clinic. Dr. Inglefield provided an overview of his experience with various body shaping technologies used in his practice. His case studies allowed the audience to better understand the types of results that can be obtained with Syneron's non-invasive technologies.
Shimon Eckhouse, Ph.D., Founder and Chairman of the Board of Syneron Medical, said, "Syneron is ideally positioned to meet the growing worldwide demand for body shaping and skin tightening procedures requiring no downtime thanks to our unique and complementary body shaping technologies that include both our focused ultrasound and proprietary elōs technology. We are proud to offer practitioners and patients the unsurpassed safety, efficacy and comfort benefits and features of our world-class UltraShape and VelaShape body shaping products."
Louis Scafuri, Chief Executive Officer of Syneron Medical, said, "Syneron is committed to providing our customers with innovative, science-based technologies to address high growth aesthetic categories that can help develop their practices. Body shaping is one of the most in-demand procedures around the world and we are committing dedicated research and development resources to ensure that we maintain and expand our leadership position in this important segment of the market. We recently began selling the UltraShape system directly in Canada and look forward to potential U.S. marketing clearance in 2013."
About Syneron Medical Ltd.Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS